Anthem Bioscienc Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q3 FY26 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.

Published 14 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹50.1K Cr

Anthem expects steady progress in revenue with a mid-teens growth (around 15%-16%) for FY26, despite a high base last year. Anthem Biosciences expects steady topline and bottom-line growth with potential to sustain a CAGR similar to the last five years over the next few years.

From Anthem Bioscienc's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹871

Market Cap

₹50.1K Cr

P/E Ratio

84.5

How does Anthem Bioscienc rank in Pharmaceuticals & Biotechnology?

Compare Anthem Bioscienc against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Anthem Bioscienc — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹611 Cr, net profit ₹190 Cr.

Full financials →

📊 Revenue & Sales Performance

→Anthem expects steady progress in revenue with a mid-teens growth (around 15%-16%) for FY26, despite a high base last year.
→Improvement anticipated in FY27 and FY28, with optimism about returning to approximately 20% growth CAGR over the next five years.
→Growth drivers include ramp-up of recently commercialized products, existing commercial products expanding market share, new large pharma customers, and increased demand post-destocking.
→Pipeline is robust with 130-140 early-stage molecules and 6 in Phase-2 likely to move to Phase-3 in 18-30 months.
→Positive outlook on biotech sector tailwinds due to government encouragement and trade deals.
→GLP-1 peptides expected to become significant contributors, though not exceeding 20%-30% of turnover.
→Specialty ingredients growth driven by GLP-1, probiotics, and biosimilars.
→Margin improvements expected to sustain due to backward integration and operating leverage.

📈 Profitability & Margins

→Anthem Biosciences expects steady topline and bottom-line growth with potential to sustain a CAGR similar to the last five years over the next few years.
→FY27 growth visibility is positive but uncertain; management is optimistic but cautious due to market lumpiness.
→Q4 FY26 typically strongest quarter; full-year revenue growth expected around mid-teens (15-16%).
→EBITDA margin trending north with aspirations to maintain or improve above 40%; full-year FY26 EBITDA growth guidance is 20%+.
→PAT margin expected to remain strong, with 20%+ growth guidance for FY26.
→Growth drivers include ramp-up of recently commercialized products, expansion in specialty ingredients (GLP-1, probiotics, biosimilars), and increased capacity (Unit-4 CAPEX underway).
→Destocking pressures affecting recent quarters expected to normalize, leading to stronger demand in coming years.
→Currency appreciation benefits recognized as other income supporting margins.
→Overall outlook remains positive given regulatory, trade improvements, and expanded customer base.

See what Anthem Bioscienc said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→Unit-4 Expansion: Rs. 1,000 crore CAPEX planned over two years for Unit-4 on a 30-acre land parcel; currently in early stage with ongoing civil work. Major CAPEX spend expected in FY27.
→New Capacity for Biosimilars: A separate new facility planned for CHO cell-based mammalian biosimilars beyond current 200-liter capacity.
→16 KL Peptide Facility: Replacement cost estimated at about Rs. 200 crore including utilities; already commissioned a state-of-the-art 16 KL commercial peptide manufacturing facility.
→Capacity Planning: Expansion is done proactively based on pipeline progress to attract and handle more projects; focus on Greenfield builds to meet high regulatory and customer standards.
→Backward Integration: Completed discontinuation of China-sourced intermediates, now fully backward integrated, contributing to margin improvements and strategic self-reliance.

💰 Fundraising & Capital Structure

→The transcript provided does not mention any current or future plans for fundraising through debt or equity by Anthem Biosciences Limited.
→There is no discussion about issuing new shares, raising capital, or taking on additional debt in the Q3 & 9M FY26 earnings call.
→The focus is primarily on organic growth through investments in technology, capacity expansion (e.g., Unit-4 CAPEX), and operational performance.
→Management emphasizes strong financial health with growing EBITDA and PAT margins, but no specific fundraising plans are disclosed.
→Any future fundraising, if planned, was not communicated in the available excerpts from the February 2026 earnings call.

See what Anthem Bioscienc said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

→Anthem Biosciences currently has a robust order book with around 130 to 140 early-stage pipeline molecules.
→Approximately 5 to 6 molecules are in Phase 2, expected to move to Phase 3 within 18 to 30 months, subject to clinical outcomes.
→Six molecules remain in Phase 3, with 4 recently commercialized.
→The company has added multiple large pharma customers this year, including supply of advanced intermediates and development work for approved products.
→There has been an increase in requests for RFQs (Request for Quotations) in recent quarters, indicating growing demand.
→Anthem is seeing signs of recovery post-destocking by customers, which had temporarily softened performance.
→The management anticipates continued strong order inflow and a positive outlook, supported by new product launches and expansion in biotech and specialty ingredients segments.

Key Metrics

How does Anthem Bioscienc rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Anthem Bioscienc

See full Pharmaceuticals & Biotechnology sector rankings

What ANTHEM's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

ONESOURCE (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
MANKIND (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
GLAND (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
SHILPAMED (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…

Compare:vs SUNPHARMA vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Anthem Bioscienc Q3 FY26 results?

What is Anthem Bioscienc share price analysis?

Anthem Bioscienc currently shows a neutral. The stock trades at a P/E of 84.5 with a market cap of ₹50,132 Cr. Investors should review the full earnings analysis for detailed insights.

Is Anthem Bioscienc planning capital expenditure?

Unit-4 Expansion: Rs.

Keep Anthem Bioscienc on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.